Cargando…

A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season

BACKGROUND: Respiratory syncytial virus (RSV) is an important pathogen causing annual epidemics of bronchiolitis and pneumonia among infants worldwide. High-risk infants currently receive RSV prophylaxis with palivizumab, a humanized RSV monoclonal antibody (MAb). In preclinical in vitro and in vivo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fernández, Pilar, Trenholme, Adrian, Abarca, Katia, Griffin, M Pamela, Hultquist, Micki, Harris, Brian, Losonsky, Genevieve A
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2010
Materias:	Research article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2898783/ https://www.ncbi.nlm.nih.gov/pubmed/20525274 http://dx.doi.org/10.1186/1471-2431-10-38

Ejemplares similares

Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV)
por: Bollani, Lina, et al.
Publicado: (2015)

Reformatting palivizumab and motavizumab from IgG to human IgA impairs their efficacy against RSV infection in vitro and in vivo
por: Jacobino, Shamir R., et al.
Publicado: (2018)

Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants
por: Mejías, Asunción, et al.
Publicado: (2008)

Motavizumab, A Neutralizing Anti-Respiratory Syncytial Virus (Rsv) Monoclonal Antibody Significantly Modifies The Local And Systemic Cytokine Responses Induced By Rsv In The Mouse Model
por: Mejías, Asunción, et al.
Publicado: (2007)

A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS)
por: Paes, B., et al.
Publicado: (2012)

Respiratory syncytial virus and palivizumab prophylaxis in the COVID-19 era
por: Taylor, Richard S.
Publicado: (2021)

Randomized, Double-Blind Study of the Pharmacokinetics and Safety of Palivizumab Liquid Formulation Compared with Lyophilized Formulation
por: Robbie, Gabriel J., et al.
Publicado: (2014)

Review of the Safety, Efficacy and Tolerability of Palivizumab in the Prevention of Severe Respiratory Syncytial Virus (RSV) Disease
por: O’Hagan, Shaun, et al.
Publicado: (2023)

Palivizumab Prophylaxis for Respiratory Syncytial Virus: Examining the Evidence Around Value
por: Olchanski, Natalia, et al.
Publicado: (2018)

Respiratory Syncytial Virus Infection in High-risk Infants – an Update on Palivizumab Prophylaxis
por: Resch, Bernhard
Publicado: (2014)

Utilization Management Opportunities for Palivizumab for Prophylaxis of Respiratory Syncytial Virus Complications in Infants
por: Curtiss, Frederic R., et al.
Publicado: (2010)

Palivizumab: a review of its use in the protection of high risk infants against respiratory syncytial virus (RSV)
por: Geskey, Joseph M, et al.
Publicado: (2007)

Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants
por: Chirico, Gaetano, et al.
Publicado: (2009)

Hyper-Enriched Anti-RSV Immunoglobulins Nasally Administered: A Promising Approach for Respiratory Syncytial Virus Prophylaxis
por: Jacque, Emilie, et al.
Publicado: (2021)

Utilization of chronic lung disease treatment before the respiratory syncytial virus season as palivizumab prophylaxis qualifier in the American Academy of Pediatrics Guidelines
por: Choi, Yoonyoung, et al.
Publicado: (2021)

A Systematic Review of Compliance with Palivizumab Administration for RSV Immunoprophylaxis
por: Frogel, Michael
Publicado: (2010)

Trends in Utilization of Outpatient Respiratory Syncytial Virus Prophylaxis with Palivizumab among Medicaid- and Commercially Insured Infants
por: Pavilack, Melissa, et al.
Publicado: (2017)

Palivizumab Compliance by Infants in Puerto Rico During the 2009–2010 Respiratory Syncytial Virus Season
por: Matías, Israel, et al.
Publicado: (2014)

Respiratory Syncytial Virus Prophylaxis in Infants With Congenital Diaphragmatic Hernia in the Canadian Respiratory Syncytial Virus Evaluation Study of Palivizumab, 2005–2017
por: Kim, Doyoung, et al.
Publicado: (2019)

Immune Prophylaxis Targeting the Respiratory Syncytial Virus (RSV) G Protein
por: Bergeron, Harrison C., et al.
Publicado: (2023)

Guidelines for palivizumab prophylaxis in infants and young children at increased risk for respiratory syncytial virus infection in Saudi Arabia
por: Al Aql, Fahad, et al.
Publicado: (2016)

Respiratory syncytial virus-neutralizing serum antibody titers in infants following palivizumab prophylaxis with an abbreviated dosing regimen
por: Claydon, Jennifer, et al.
Publicado: (2017)

Impact of Palivizumab on RSV Hospitalizations for Children with Hemodynamically Significant Congenital Heart Disease
por: Chang, Ruey-Kang R., et al.
Publicado: (2009)

Palivizumab reimbursement criteria and neonatal RSV hospitalisation: a regional retrospective review
por: Belleudi, Valeria, et al.
Publicado: (2021)

Compliance with The RSV Immunoprophylaxis Dosing Schedule in The Polish Registry for Palivizumab (2008-2014)
por: Borecka, Róża, et al.
Publicado: (2019)

Economic results of a palivizumab seasonal prophylaxis using a cohorting software and vial sharing
por: Coletta, Elio, et al.
Publicado: (2010)

Impact of the Withdrawal of Palivizumab Immunoprophylaxis on the Incidence of Respiratory Syncytial Virus (RSV) Hospitalizations Among Infants Born at 33 to 35 Weeks’ Gestational Age in the Province of Quebec, Canada: The RSV-Quebec Study
por: Papenburg, Jesse, et al.
Publicado: (2020)

Prophylaxis protects infants with congenital heart disease from severe forms of RSV infection: an Italian observational retrospective study: Palivizumab prophylaxis in children with congenital heart disease
por: Ratti, Chiara, et al.
Publicado: (2023)

The impact of the recent AAP changes in palivizumab authorization on RSV-induced bronchiolitis severity and incidence
por: Capizzi, Antonino, et al.
Publicado: (2017)

Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain
por: Sanchez-Luna, M., et al.
Publicado: (2017)

Palivizumab prophylaxis against respiratory syncytial virus infection in patients younger than 2 years of age with congenital heart disease
por: Mohammed, Mohammed Hassan A., et al.
Publicado: (2021)

Review of the home care programmes for respiratory syncytial virus (RSV) prophylaxis in Ireland and The Netherlands
por: Whelan, Barbara, et al.
Publicado: (2016)

Respiratory Syncytial Virus (RSV)
por: Walsh, Edward E., et al.
Publicado: (2015)

Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective
por: Homaira, Nusrat, et al.
Publicado: (2014)

Partial palivizumab prophylaxis and increased risk of hospitalization due to respiratory syncytial virus in a Medicaid population: a retrospective cohort analysis
por: Krilov, Leonard R, et al.
Publicado: (2014)

Palivizumab Prophylaxis among Infants at Increased Risk of Hospitalization due to Respiratory Syncytial Virus Infection in UAE: A Hospital-Based Study
por: Elhalik, M., et al.
Publicado: (2019)

Evaluation of a Novel Web-Based Prior Approval Application for Palivizumab Prophylaxis of Respiratory Syncytial Virus in a State Medicaid Program
por: Lundeen, Kristin, et al.
Publicado: (2013)

Reappraisal of the Subtropical Guidelines on Palivizumab Prophylaxis in Congenital Heart Disease
por: Chiu, Shuenn-Nan, et al.
Publicado: (2022)

Molecular characterization of respiratory syncytial viruses infecting children reported to have received palivizumab immunoprophylaxis
por: Oliveira, Danielle B.L., et al.
Publicado: (2015)

Assessing Variation in the Cost of Palivizumab for Respiratory Syncytial Virus Prevention in Preterm Infants
por: Shahabi, Ahva, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_bmttr7fatdb3iiijek4k8789jr